Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc. (NASDAQ:INAB) reported 2024 financial ...

INB Homes announced today that Villas at King's Landing is now selling in Fort Pierce. The announcement follows a February 11 event with local Realtors, business leaders and city officials marking the ...

IN8bio announces INB-619, a novel γδ T cell therapy platform targeting CD19, showing promise in B cell depletion with reduced side effects. IN8bio, Inc. has announced the launch of its innovative γδ T ...

IN8bio anticipates 2024 data for leukemia & glioblastoma therapies, plans FDA talks on glioblastoma programs after promising survival data, and advances autoimmune disease candidate.

IN8bio’s are centered on populating the expansion cohort for the INB-100 trial. The scientific team has met with the FDA in a Type B meeting to help guide the design of the registrational path for INB ...

Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp ...

INB-200 shows significantly improved progression-free survival in glioblastoma patients, with favorable safety profile and no serious toxicities reported. Repeated doses of INB-200 demonstrated an ...

IN8bio (NASDAQ:INAB) stock rose ~110% on Monday after the company reported data from a phase 1 trial of INB-100 in patients with leukemia. The company said that data showed that 100% of evaluable ...

Patients treated with INB-100 demonstrating prolonged and durable remissions supported by gamma-delta T cell persistence beyond one year Company to host conference call at 8:30am EST today. Use this ...

Indústrias Nucleares do Brasil has signed a contract with Amazônia Azul Technologias de Defesa SA (Amazul) to provide engineering services for the second phase of the uranium enrichment plant at INB's ...